Earnings call analysis

Natera (NTRA) Q3 FY2026 Earnings Call: Guidance and Outlook

Management provided formal guidance for the full year 2026, raising revenue expectations and adjusting expense ranges while maintaining gross margin targets.

About Natera. Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally.

Call date

Nov 5, 2026

Sentiment score

+35 Balanced

Management tone, -100 to +100

Sentiment change

vs Q2 2026 call

Sector

Health Care, Biotechnology

Next report

Feb 25, 2027

View calendar

Quarterly guidance

Quarterly guidance: No formal quarterly guidance figures were issued for Q4 on the call.

Annual guidance

Revenue: $3.35 billion to $3.5 billion
Gross margin: 64% to 66%
R&D: Top end of the range bumped by $25 million
SG&A: Bumped to $1.3 billion at the top end

Outlook

2027 Planning: Management expects 2027 to be another growth year across the board, assuming continued unit growth and relatively steady ASPs.
OpEx Growth: Preliminary planning for 2027 implies OpEx growth in the 10% to 12% range to support ongoing investments in ECD and MRD clinical trials.
Long-Term Revenue Goal: Natera set a long-term goal to reach $6 billion in revenue in 2029 through core oncology growth, global expansion, and pharma demand.
Pharma and Data Demand: Pharma and data services demand is expected to continue increasing significantly, supported by expanded investments and new commercial offerings.

Sources and method

Dombey's summary of the Natera Q3 FY2026 earnings call held Nov 5, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.

Updated Nov 8, 2026. All earnings call analyses

Research access

Research published before the catalyst, kept on the record after it.

Public ArchiveComplimentaryA starting point for exploring our independent perspective on global equities through published executive theses and publicly available research.Read public research Standard Access$6.67 / monthOngoing catalyst coverage and the complete public-research archive, for readers who want to follow forthcoming events and revisit the firm's published thinking.Start Standard Access RecommendedFounding Membership$1,200 / yearInstitutional access to the complete research suite, proprietary models and execution strategy.Become a Founding Member